Search

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

… Monday, October 31, 2016 Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment

Learn how our donor community is supporting MSK research and education.

… Thursday, April 1, 2021 Every day, your dollars are accelerating today’s most daring discoveries straight into lifesaving care. Read more to learn about your impact. The Society of Memorial Sloan Kettering Winter Lunch On February 3, The Society of MSK hosted its eighth annual Winter Lunch to support

A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.

… Friday, May 31, 2019 Summary The National Cancer Institute recently awarded MSK a prestigious SPORE grant for bladder cancer research. Learn about how MSK researchers will use the $6.5 million award to gain insights into how the disease develops and responds to treatment. Bladder cancer is the fifth

Several types of cancer were once strongly linked to an AIDS diagnosis. Thanks to improved HIV medications, that's changing.

… Wednesday, April 3, 2019 Summary People with HIV are sometimes susceptible to getting specific types of cancer. This association has changed over the years, as drugs to control HIV infection have become available. When the AIDS epidemic began in 1981, many of the first reported cases were young gay men

A drug combination that halts tumor cell division can stir the immune system into taking action.

… Thursday, December 20, 2018 Summary According to scientists at the Sloan Kettering Institute, a two-drug combination that doesn’t directly kill tumor cells can still help as a cancer treatment. The key is activating the immune system. The goal of most cancer-fighting drugs is to kill tumor cells. But

In what is being hailed as a watershed moment for both cancer care and biotechnology, the US Food and Drug Administration has approved a personalized, cell-based immunotherapy for use in children and young adults with blood cancer. For more information or to arrange interviews, e-mail Caitlin Hool at [email protected].

… Tuesday, September 5, 2017 The FDA has approved a new type of immunotherapy called chimeric antigen receptor (CAR) T cell therapy . In this approach, scientists genetically engineer a patient’s own immune cells to make a new protein that can latch onto cancer. This turns them into supercharged cancer

A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial (NCT04093596) published recently in Nature Medicine.

… Wednesday, February 15, 2023 A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial ( NCT04093596 )

NBC News anchor Craig Melvin led MSK experts in a discussion about racial and age trends in colorectal cancer and when people should start screening for the disease.

… Monday, September 19, 2022 NBC News’ Today Show anchor and co-host Craig Melvin led a discussion at Memorial Sloan Kettering Cancer Center (MSK) in March 2022 with colorectal oncologists  Fiyinfolu Balogun  and  Andrea Cercek and gastroenterologist  Robin Mendelsohn . Drs. Cercek and Mendelsohn are Co-Directors

R1 RCM Inc. and Memorial Sloan Kettering today announced a collaboration to develop a new, personalized digital financial experience for patients.

… Monday, November 1, 2021 R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, through its recent acquisition of VisitPay, today announced a collaboration with Memorial Sloan Kettering Cancer

A clinical trial at MSK found that music therapy for cancer-related anxiety is as effective as cognitive behavioral therapy and produces long-lasting benefits.

… Tuesday, January 6, 2026 Anxiety was not new to Cynthia Malaran when she was diagnosed with breast cancer , at the age of 39. The professional DJ and writer from New York City had seen a therapist to help with her feelings of anxiety in the past, but a cancer diagnosis and treatment had made it harder